Evidence map›Paper›PMID 41664740›Full record

ArticleCureus2026

Topical Tacrolimus 0.1% in the Treatment of Thygeson's Superficial Punctate Keratitis.

Audrey-Anne Lapierre, Mélanie Hébert, René Dinh

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Audrey-Anne LapierreDepartment of Ophthalmology, Université Laval, Quebec, CAN.
Mélanie HébertDepartment of Ophthalmology, Hôpital du Saint-Sacrement, Quebec, CAN.
René DinhDepartment of Ophthalmology, Hôpital du Saint-Sacrement, Quebec, CAN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thygeson's superficial punctate keratitis (TSPK) is a rare and chronic eye condition characterized by recurrent flare-ups of symptoms such as photophobia and tearing. Various treatments have been attempted over the years, but none have been entirely successful in managing the condition. This report presents the case of a 21-year-old woman with bilateral TSPK who exhibited photophobia, tearing, and burning sensations. The patient was treated with an off-label non-ophthalmic topical tacrolimus 0.1% ointment, applied nightly into the inferior fornix and titrated with artificial tears to improve tolerance. Complete resolution of corneal lesions and symptoms was observed after three weeks, so the treatment was stopped. Although lesions reappeared following cessation of treatment, symptomatic relief persisted. This case highlights the potential of non-ophthalmic tacrolimus 0.1% ointment, a higher-concentration formulation not previously described in the TSPK literature, as an effective therapeutic option that may contribute to prolonged symptom control while avoiding the intraocular pressure risks associated with steroid use, particularly in young patients. Tacrolimus may represent a promising alternative therapy for patients requiring chronic management of TSPK.

Indexed as

chronic keratitiscornea pathologyimmunomodulatory therapysteroid-sparing treatmentthygeson’s superficial punctate keratitistopical tacrolimus

Identifiers

PMID41664740
PMCPMC12883179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.